cpass sars-cov-2 positive control Search Results


90
GenScript corporation cpass sars-cov-2 surrogate virus neutralization test kit ref#l00847-c
Cpass Sars Cov 2 Surrogate Virus Neutralization Test Kit Ref#L00847 C, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass sars-cov-2 surrogate virus neutralization test kit ref#l00847-c/product/GenScript corporation
Average 90 stars, based on 1 article reviews
cpass sars-cov-2 surrogate virus neutralization test kit ref#l00847-c - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GenScript corporation cpass sars-cov-2 neutralization antibody detection kit
Cpass Sars Cov 2 Neutralization Antibody Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass sars-cov-2 neutralization antibody detection kit/product/GenScript corporation
Average 90 stars, based on 1 article reviews
cpass sars-cov-2 neutralization antibody detection kit - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GenScript corporation cpass ® sars-cov-2 neutralization antibody detection kit
Cpass ® Sars Cov 2 Neutralization Antibody Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass ® sars-cov-2 neutralization antibody detection kit/product/GenScript corporation
Average 90 stars, based on 1 article reviews
cpass ® sars-cov-2 neutralization antibody detection kit - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
EUROIMMUN sars-cov-2-neutralisa
Sars Cov 2 Neutralisa, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sars-cov-2-neutralisa/product/EUROIMMUN
Average 90 stars, based on 1 article reviews
sars-cov-2-neutralisa - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
SD Biosensor standard e sars-cov-2 nab elisa kit
Standard E Sars Cov 2 Nab Elisa Kit, supplied by SD Biosensor, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/standard e sars-cov-2 nab elisa kit/product/SD Biosensor
Average 90 stars, based on 1 article reviews
standard e sars-cov-2 nab elisa kit - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Medac GmbH elisa-based sars-cov-2 rbd-ace2 binding inhibition assay (surrogate sars-cov-2 neutralization test (svnt) cpass
(A) Anti-S1 IgG in serum measured by a microarray-based immunoassay, (B) serum pseudovirus neutralization against the Delta VOC two and six months after vaccination measured by pNT, and (C) <t>SARS-CoV-2</t> S1 specific T cell response detected by IGRA. Dotted horizontal lines indicate themanufacturer’s threshold for anti-S1 IgG ≥1 S/Co (A) and the lower limit of detection (1:10 dilution) for pNT (B). Horizontal lines within plotted data regions indicate the median and interquartile range, except for pNT, where the geometric mean and 95% confidence interval is shown. P values (all <0.0001) were calculated by non-parametric Mann Whitney U test. S/Co: signal-to-cutoff, pNT: pseudovirus neutralization test, ID 50 : 50% inhibition dilution, IGRA: interferon-γ release assay, IU: international units.
Elisa Based Sars Cov 2 Rbd Ace2 Binding Inhibition Assay (Surrogate Sars Cov 2 Neutralization Test (Svnt) Cpass, supplied by Medac GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa-based sars-cov-2 rbd-ace2 binding inhibition assay (surrogate sars-cov-2 neutralization test (svnt) cpass/product/Medac GmbH
Average 90 stars, based on 1 article reviews
elisa-based sars-cov-2 rbd-ace2 binding inhibition assay (surrogate sars-cov-2 neutralization test (svnt) cpass - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GenScript corporation surrogate virus neutralisation test (svnt) for sars-cov-2 cpass
(A) Anti-S1 IgG in serum measured by a microarray-based immunoassay, (B) serum pseudovirus neutralization against the Delta VOC two and six months after vaccination measured by pNT, and (C) <t>SARS-CoV-2</t> S1 specific T cell response detected by IGRA. Dotted horizontal lines indicate themanufacturer’s threshold for anti-S1 IgG ≥1 S/Co (A) and the lower limit of detection (1:10 dilution) for pNT (B). Horizontal lines within plotted data regions indicate the median and interquartile range, except for pNT, where the geometric mean and 95% confidence interval is shown. P values (all <0.0001) were calculated by non-parametric Mann Whitney U test. S/Co: signal-to-cutoff, pNT: pseudovirus neutralization test, ID 50 : 50% inhibition dilution, IGRA: interferon-γ release assay, IU: international units.
Surrogate Virus Neutralisation Test (Svnt) For Sars Cov 2 Cpass, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/surrogate virus neutralisation test (svnt) for sars-cov-2 cpass/product/GenScript corporation
Average 90 stars, based on 1 article reviews
surrogate virus neutralisation test (svnt) for sars-cov-2 cpass - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GenScript corporation cpass surrogate virus neutralization test (svnt)
Analysis of mAb 9G8 blocking the SARS-CoV-2 spike RBD variant from binding to the human ACE2 receptor by surrogate virus <t>neutralization</t> test <t>(sVNT).</t> The percent inhibition of mAb 9G8 was measured against RBD of SARS-CoV-2 WT or SARS-CoV-2 variants such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), Delta Plus/AY.1 (B.1.617.2.1), and Epsilon (B.1.429/7). The mAb 6C8 specific for nucleocapsid protein was used as a negative control. The results were expressed as the arithmetic mean of percent-blocking values of triplicates and ±SD of the mean.
Cpass Surrogate Virus Neutralization Test (Svnt), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass surrogate virus neutralization test (svnt)/product/GenScript corporation
Average 90 stars, based on 1 article reviews
cpass surrogate virus neutralization test (svnt) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GenScript corporation cpass assay
Analysis of mAb 9G8 blocking the SARS-CoV-2 spike RBD variant from binding to the human ACE2 receptor by surrogate virus <t>neutralization</t> test <t>(sVNT).</t> The percent inhibition of mAb 9G8 was measured against RBD of SARS-CoV-2 WT or SARS-CoV-2 variants such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), Delta Plus/AY.1 (B.1.617.2.1), and Epsilon (B.1.429/7). The mAb 6C8 specific for nucleocapsid protein was used as a negative control. The results were expressed as the arithmetic mean of percent-blocking values of triplicates and ±SD of the mean.
Cpass Assay, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass assay/product/GenScript corporation
Average 90 stars, based on 1 article reviews
cpass assay - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
AstraZeneca ltd cpass sars-cov2 neutralizing antibody assay
Analysis of mAb 9G8 blocking the SARS-CoV-2 spike RBD variant from binding to the human ACE2 receptor by surrogate virus <t>neutralization</t> test <t>(sVNT).</t> The percent inhibition of mAb 9G8 was measured against RBD of SARS-CoV-2 WT or SARS-CoV-2 variants such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), Delta Plus/AY.1 (B.1.617.2.1), and Epsilon (B.1.429/7). The mAb 6C8 specific for nucleocapsid protein was used as a negative control. The results were expressed as the arithmetic mean of percent-blocking values of triplicates and ±SD of the mean.
Cpass Sars Cov2 Neutralizing Antibody Assay, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass sars-cov2 neutralizing antibody assay/product/AstraZeneca ltd
Average 90 stars, based on 1 article reviews
cpass sars-cov2 neutralizing antibody assay - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GenScript corporation cpass neutralisation antibody detection kit
Analysis of mAb 9G8 blocking the SARS-CoV-2 spike RBD variant from binding to the human ACE2 receptor by surrogate virus <t>neutralization</t> test <t>(sVNT).</t> The percent inhibition of mAb 9G8 was measured against RBD of SARS-CoV-2 WT or SARS-CoV-2 variants such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), Delta Plus/AY.1 (B.1.617.2.1), and Epsilon (B.1.429/7). The mAb 6C8 specific for nucleocapsid protein was used as a negative control. The results were expressed as the arithmetic mean of percent-blocking values of triplicates and ±SD of the mean.
Cpass Neutralisation Antibody Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass neutralisation antibody detection kit/product/GenScript corporation
Average 90 stars, based on 1 article reviews
cpass neutralisation antibody detection kit - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GenScript corporation genscript cpass kit
Analysis of mAb 9G8 blocking the SARS-CoV-2 spike RBD variant from binding to the human ACE2 receptor by surrogate virus <t>neutralization</t> test <t>(sVNT).</t> The percent inhibition of mAb 9G8 was measured against RBD of SARS-CoV-2 WT or SARS-CoV-2 variants such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), Delta Plus/AY.1 (B.1.617.2.1), and Epsilon (B.1.429/7). The mAb 6C8 specific for nucleocapsid protein was used as a negative control. The results were expressed as the arithmetic mean of percent-blocking values of triplicates and ±SD of the mean.
Genscript Cpass Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/genscript cpass kit/product/GenScript corporation
Average 90 stars, based on 1 article reviews
genscript cpass kit - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


(A) Anti-S1 IgG in serum measured by a microarray-based immunoassay, (B) serum pseudovirus neutralization against the Delta VOC two and six months after vaccination measured by pNT, and (C) SARS-CoV-2 S1 specific T cell response detected by IGRA. Dotted horizontal lines indicate themanufacturer’s threshold for anti-S1 IgG ≥1 S/Co (A) and the lower limit of detection (1:10 dilution) for pNT (B). Horizontal lines within plotted data regions indicate the median and interquartile range, except for pNT, where the geometric mean and 95% confidence interval is shown. P values (all <0.0001) were calculated by non-parametric Mann Whitney U test. S/Co: signal-to-cutoff, pNT: pseudovirus neutralization test, ID 50 : 50% inhibition dilution, IGRA: interferon-γ release assay, IU: international units.

Journal: medRxiv

Article Title: Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

doi: 10.1101/2021.08.26.21262468

Figure Lengend Snippet: (A) Anti-S1 IgG in serum measured by a microarray-based immunoassay, (B) serum pseudovirus neutralization against the Delta VOC two and six months after vaccination measured by pNT, and (C) SARS-CoV-2 S1 specific T cell response detected by IGRA. Dotted horizontal lines indicate themanufacturer’s threshold for anti-S1 IgG ≥1 S/Co (A) and the lower limit of detection (1:10 dilution) for pNT (B). Horizontal lines within plotted data regions indicate the median and interquartile range, except for pNT, where the geometric mean and 95% confidence interval is shown. P values (all <0.0001) were calculated by non-parametric Mann Whitney U test. S/Co: signal-to-cutoff, pNT: pseudovirus neutralization test, ID 50 : 50% inhibition dilution, IGRA: interferon-γ release assay, IU: international units.

Article Snippet: Functional neutralization capacity was investigated using a commercially available ELISA-based SARS-CoV-2 RBD-ACE2 binding inhibition assay (surrogate SARS-CoV-2 neutralization test (sVNT) cPass (medac GmbH, https://international.medac.de ).

Techniques: Microarray, Neutralization, MANN-WHITNEY, Inhibition, Release Assay

( A ) Anti-SARS-CoV-2 N, ( B ) RBD- ( C ) and full-spike IgG measured in the serum of BNT162b2 vaccinated HCW and elderly persons six months after the first vaccination. ( D ) Neutralizing capacity was measured by sVNT and ( E ) serum neutralization against Alpha (B.1.1.7) VOC detected by pNT in vaccinated HCW and elderly persons six months after the first vaccination. ( F ) Binding capacity of serum IgG against six different RBDs of SARS-CoV-2 variants carrying the indicated mutations in HCW and elderly, measured by ELISA. Dotted lines indicate the manufacturer’s threshold values: for anti-N, anti-RBD, and anti-full spike IgG ≥1 S/Co, for sVNT >30%, and the lower limit of detection (1:10 dilution) for pNT. Lines indicate the median and interquartile range except for pNT, where the geometric mean and 95% confidence interval are shown. P values were calculated by the non-parametric Mann Whitney U test or Kruskal-Wallis test with Dunn’s multiple comparisons test. S/Co: signal-to-cutoff, N: nucleocapsid protein, RBD: receptor-binding domain, sVNT: surrogate virus neutralization test, ACE2: angiotensin-converting enzyme 2, ID50: 50% inhibition dilution.

Journal: medRxiv

Article Title: Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

doi: 10.1101/2021.08.26.21262468

Figure Lengend Snippet: ( A ) Anti-SARS-CoV-2 N, ( B ) RBD- ( C ) and full-spike IgG measured in the serum of BNT162b2 vaccinated HCW and elderly persons six months after the first vaccination. ( D ) Neutralizing capacity was measured by sVNT and ( E ) serum neutralization against Alpha (B.1.1.7) VOC detected by pNT in vaccinated HCW and elderly persons six months after the first vaccination. ( F ) Binding capacity of serum IgG against six different RBDs of SARS-CoV-2 variants carrying the indicated mutations in HCW and elderly, measured by ELISA. Dotted lines indicate the manufacturer’s threshold values: for anti-N, anti-RBD, and anti-full spike IgG ≥1 S/Co, for sVNT >30%, and the lower limit of detection (1:10 dilution) for pNT. Lines indicate the median and interquartile range except for pNT, where the geometric mean and 95% confidence interval are shown. P values were calculated by the non-parametric Mann Whitney U test or Kruskal-Wallis test with Dunn’s multiple comparisons test. S/Co: signal-to-cutoff, N: nucleocapsid protein, RBD: receptor-binding domain, sVNT: surrogate virus neutralization test, ACE2: angiotensin-converting enzyme 2, ID50: 50% inhibition dilution.

Article Snippet: Functional neutralization capacity was investigated using a commercially available ELISA-based SARS-CoV-2 RBD-ACE2 binding inhibition assay (surrogate SARS-CoV-2 neutralization test (sVNT) cPass (medac GmbH, https://international.medac.de ).

Techniques: Neutralization, Binding Assay, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY, Inhibition

Analysis of mAb 9G8 blocking the SARS-CoV-2 spike RBD variant from binding to the human ACE2 receptor by surrogate virus neutralization test (sVNT). The percent inhibition of mAb 9G8 was measured against RBD of SARS-CoV-2 WT or SARS-CoV-2 variants such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), Delta Plus/AY.1 (B.1.617.2.1), and Epsilon (B.1.429/7). The mAb 6C8 specific for nucleocapsid protein was used as a negative control. The results were expressed as the arithmetic mean of percent-blocking values of triplicates and ±SD of the mean.

Journal: Viruses

Article Title: Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants

doi: 10.3390/v14020230

Figure Lengend Snippet: Analysis of mAb 9G8 blocking the SARS-CoV-2 spike RBD variant from binding to the human ACE2 receptor by surrogate virus neutralization test (sVNT). The percent inhibition of mAb 9G8 was measured against RBD of SARS-CoV-2 WT or SARS-CoV-2 variants such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), Delta Plus/AY.1 (B.1.617.2.1), and Epsilon (B.1.429/7). The mAb 6C8 specific for nucleocapsid protein was used as a negative control. The results were expressed as the arithmetic mean of percent-blocking values of triplicates and ±SD of the mean.

Article Snippet: To determine the neutralizing activity of mAbs against SARS-CoV-2 variants, a GenScript cPASS surrogate virus neutralization test (sVNT) was performed according to manufacturer’s instructions (GenScript, Piscataway, NJ, USA).

Techniques: Blocking Assay, Variant Assay, Binding Assay, Virus, Neutralization, Inhibition, Negative Control